119034-31-0

Upstream product

• 119034-77-4 2,3-dimethoxy-6,7-dihydro-5H-benzocycloheptene-8-carboxylic acid 
• 964-65-8 piperazin-1-yl-(3,4,5,trimethoxy-phenyl)-methanone 
• 119049-60-4 2,3-dimethoxy-6,7-dihydro-5H-benzocyclohepten-8-carbonyl chloride 
• 2942-58-7 diethyl cyanophosphonate 
• 119034-74-1 1-(2,3-dimethoxy-6,7-dihydro-5H-benzocyclohepten-8-ylcarbonyl)piperazine 
• 118-41-2 Eudesmic acid 
• 4521-61-3 3,4,5-Trimethoxybenzoyl chloride 
• 119034-76-3 5-Hydroxy-2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzocycloheptene-6-carboxylic acid 
• 119034-75-2 2,3-dimethoxy-5-hydroxy-6,7,8,9-tetrahydro-5H-benzocycloheptene-6-carboxylic acid methyl ester 
• 119049-68-2 methyl 2,3-dimethoxy-5-oxo-6,7,8,9-tetrahydro-5H-benzocycloheptene-6-carboxylate 
• 951-99-5 2,3-dimethoxy-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-one 

Relevant academic research and scientific papers

Synthesis and platelet-activating factor (PAF)-antagonistic activities of 1,4-disubstituted piperazine derivatives

During the screening of novel platelet-activating factor (PAF) antagonists, we found that 1-(6-methoxy-3,4-dihydro-2-naphthoyl)-4-(3,4,5- trimethoxybenzyl)piperazine and its 4-(3,4,5-trimethoxybenzoyl)piperazine derivatives (1b, 2b) exerted in vitro and i

1,4-disubstituted piperazines (or homopiperazines) as platelet-activating factor antagonists

Novel 1,4-disubstituted piperazine compounds represented by the formula (I): STR1 wherein A is a condensed polycyclic hydrocarbon group; R is a phenyl group substituted with a lower alkoxy group; X is methylene group, carbonyl group or thiocarbonyl group; and m is 2 or 3, and their salts are useful as a platelet activating factor antagonist.